Applied DNA Sciences, Inc. APDN
At closeOct 6, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- -44.90%
- 1 year
- -69.59%
- Market cap
- 7.26M
- Revenue (ttm)
- 3.40M
- Profit margin
- -214.48%
- Shares out
- 52.29M
- Forward P/E
- -0.17
- YTD return
- -44.90%
- 1-year return
- -69.59%
- Volume
- 2.65M
- Open
- 4.70
- Previous close
- 5.62
- Day's range
- 4.61 – 5.80
- Beta
- 0.45
- Earnings date
- Feb 13, 2025
2Y -19,345.37 (-99.98%)
Key statistics
- Enterprise value
- -7.36M
- PEG ratio
- 0.00
- Price / sales
- 2.76
- Price / book
- 0.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -72.70%
- Free cash flow
- -8.28M
- Total cash
- 10.44M
- Total debt
- 868.08K
- Return on equity
- -76.08%
- Short % of float
- 3.49%
- 50-day average
- 0.2148
- 200-day average
- 2.09
Next earnings
Feb 13, 2025
Expected Feb 13, 2025. Consensus EPS estimate -0.33.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 13, 2025 | Dec 1, 2024 | -0.32 | — | — | — |
| Dec 17, 2024 | Sep 1, 2024 | -0.33 | -0.32 | +0.01 | +3.03% |
| Aug 8, 2024 | Jun 1, 2024 | -0.64 | 0.47 | +1.11 | +173.44% |
| May 10, 2024 | Mar 1, 2024 | -4.60 | -5.31 | -0.71 | -15.43% |
| Feb 8, 2024 | Dec 1, 2023 | -6.20 | -1.80 | +4.40 | +70.97% |
| Dec 7, 2023 | Sep 1, 2023 | -5.40 | -5.20 | +0.20 | +3.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 10, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 9, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 8, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 24, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Applied DNA Sciences, Inc.
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- adnas.com
News
Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX' Reflecting Digital Asset Treasury Strategy 12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket 12 Health Care Stocks Moving In Monday's After-Market Session
Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation 12 Health Care Stocks Moving In Friday's After-Market Session
Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences Earnings Scheduled For August 26, 2025
Your note
Sign in to keep a note on APDN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JANTZEN BETH M | Chief Financial Officer | Stock Award(Grant) | Mar 22, 2023 | 91,739 |
| MURRAH JUDITH | Chief Operating Officer | Stock Award(Grant) | Mar 22, 2023 | 101,853 |
| SHORROCK CLAY | Officer | Stock Award(Grant) | Mar 22, 2023 | 91,667 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AMH Equity Ltd. | 0.98% | 514,656 | 92.17K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.20% | 106,736 | 19.12K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.14% | 73,396 | 13.14K | Sep 29, 2024 |
| Baader Bank Aktiengesellschaft | 0.04% | 19,960 | 3.57K | Sep 29, 2024 |
| Atria Wealth Solutions, Inc. | 0.04% | 20,004 | 3.58K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.02% | 10,159 | 1.82K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.11% | 57,643 | 10.32K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.05% | 26,013 | 4.66K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.03% | 13,642 | 2.44K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.02% | 8,677 | 1.55K | Sep 29, 2024 |
